Nabi Discontinues StaphVax After Confirmatory Phase III Trial Fails
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Nabi Biopharmaceuticals is halting development of its Staphylococcus aureus vaccine StaphVax after the product's failure to show efficacy in a 3,600-patient confirmatory trial
You may also be interested in...
Nabi Seeking StaphVAX Indication For All At-Risk Groups; BLA By End Of 2005
Nabi is initiating immunogenicity trials of its S. aureus vaccine StaphVAX in new patient groups in hopes of securing a broad approval for use in all at-risk adults.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product